Polypeptide for delaying telomere shortening and use thereof

By providing amino acid sequence-specific peptides and compositions, telomerase activity is enhanced and β-galactosidase is inhibited, thus addressing the cellular aging and disease problems caused by telomere shortening and achieving significant delaying effects and safety.

WO2026153409A1PCT designated stage Publication Date: 2026-07-23INNOVATION CENT OF SUZHOU NANJING MEDICAL UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
INNOVATION CENT OF SUZHOU NANJING MEDICAL UNIV
Filing Date
2026-01-15
Publication Date
2026-07-23

AI Technical Summary

Technical Problem

Existing technologies are unable to effectively slow down telomere shortening, which leads to cellular aging and related diseases such as neurodegenerative diseases, cirrhosis, and kidney damage.

Method used

A polypeptide and a composition thereof, having an amino acid sequence as shown in SEQ ID NO.1 and SEQ ID NO.2, are provided that can delay telomere shortening, resist aging, and treat diseases related to telomere loss or dysfunction by increasing the expression level of telomerase reverse transcriptase, increasing the activity of telomerase, and inhibiting the expression level of β-galactosidase.

Benefits of technology

It significantly delays the cellular aging process, increases telomerase activity, and reduces β-galactosidase expression, exhibiting high bioactivity and low risk of side effects. It can be used to prepare drugs to delay telomere shortening and treat related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2026072780_23072026_PF_FP_ABST
    Figure CN2026072780_23072026_PF_FP_ABST
Patent Text Reader

Abstract

The present application relates to the technical field of biology, and relates to a polypeptide for delaying telomere shortening and a use thereof. The present application provides a polypeptide for delaying telomere shortening. The amino acid sequence of the polypeptide is as shown in SEQ ID NO. 1. Studies have shown that the polypeptide has high biological activity, and can significantly slow down cellular senescence by delaying telomere shortening, increasing the expression level of telomerase reverse transcriptase, increasing the activity of telomerase, and inhibiting the expression level of β-galactosidase. Moreover, the polypeptide is derived from a fermentation process of a natural dairy product, and has relatively high safety and a relatively low risk of side effects. In addition, the polypeptide has a relatively small molecular weight, is easily absorbed by a human body, and can improve the bioavailability of a drug. Therefore, the polypeptide has great application prospects in delaying telomere shortening, anti-aging, and treating diseases related to telomere loss or dysfunction.
Need to check novelty before this filing date? Find Prior Art